Adherence to <scp>GLP</scp> ‐1 receptor agonists and <scp>SGLT2</scp> inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes
OOP costs for GLP-1RAs and SGLT2i are substantial, potentially posing a particular burden for low-income Medicare beneficiaries. Policy changes may reduce this burden, although adherence improvements appear limited to beneficiaries using SGLT2i.
Authors
- Meyeon Park (ORCID: https://orcid.org/0000-0002-2695-0894)
- Wendy Max (ORCID: https://orcid.org/0000-0002-4040-1592)
- M. G. Myriam Hunink (ORCID: https://orcid.org/0000-0002-2942-2798)
- Ellerie Weber (ORCID: https://orcid.org/0000-0003-3179-7035)
- Umesh Masharani (ORCID: https://orcid.org/0000-0002-3269-804X)
- Bart S. Ferket (ORCID: https://orcid.org/0000-0003-2754-545X)
- Joseph Yeboah (ORCID: https://orcid.org/0000-0001-6274-5882)
- Kirsten E. Fleischmann (ORCID: https://orcid.org/0000-0002-3813-4384)
- Lihua Li (ORCID: https://orcid.org/0000-0003-3154-9576)
- Nicklas S. Klepser
Institutions
- Atrium Health Wake Forest Baptist (US)
- Massachusetts Department of Public Health (US)
- University of California, San Francisco (US)
- Erasmus MC (NL)
- Institute on Aging (US)
- Erasmus University Rotterdam (NL)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1111/dom.16619
- Citations
- 2
- Primary Topic
- Medication Adherence and Compliance
- Type
- article
- Field-Weighted Citation Impact
- 3.03
Funders
- National Heart, Lung, and Blood Institute